Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-12-02

Reporting Person: Struthers Richard Scott (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-02	Common stock	P	1000	$12.60	Acquired	1000	Indirect
2020-12-03	Common stock	P	4000	$13.10	Acquired	4000	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	890805	Indirect
Common Stock	100000	Indirect
Common Stock	100000	Indirect
Common Stock	100000	Indirect